Global and European Cannabis Pharmaceuticals Market Outlook 2025–2035

Global cannabis pharmaceuticals market set for rapid growth by 2035, driven by regulatory approvals, clinical adoption, and non-opioid therapies.



ROCKVILLE, MD, UNITED STATES, November 24, 2025 / EINPresswire.com/ -- The global cannabis pharmaceuticals market is set for exponential growth from 2025 to 2035, driven by rising regulatory approvals for cannabis-based medications, increasing clinical evidence supporting efficacy, and expanding adoption in neurological and pain management treatments. Cannabis pharmaceuticals—including FDA-approved cannabidiol formulations like Epidiolex, oromucosal sprays such as Sativex, and emerging synthetic cannabinoid therapies—are playing a crucial role in managing treatment-resistant epilepsy, chronic pain, multiple sclerosis spasticity, and other neurological conditions. This report provides insights into market size, growth drivers, regional dynamics in Europe, technology trends, and strategic implications for stakeholders.

Market Size and Growth

The global cannabis pharmaceuticals market is projected to surge from USD 1.2 billion in 2025 to USD 90.4 billion by 2035, reflecting a compound annual growth rate (CAGR) of 54.1%. Europe, a key regional market, is witnessing accelerating adoption through national medical cannabis programs and integrated pharmaceutical reimbursement policies. Epidiolex dominates with a 65.2% market share in 2025, while seizures remain the largest therapeutic segment, accounting for 42.5% of applications.

To access the complete data tables and in-depth insights, request a Discount On The Report here: https://www.factmr.com/connectus/sample?flag=S&rep_id=11795

Key Growth Drivers

Regulatory approvals and clinical validation:Expanding evidence-based research supports

cannabis pharmaceuticals for epilepsy, chronic pain, and multiple sclerosis management.
Rising acceptance of medical cannabis:Expanding prescription authorizations across Europe enhance patient access and treatment adoption.
Non-opioid alternatives for pain management:Growing demand for safer analgesics and anticonvulsants fuels pharmaceutical-grade cannabis adoption.
Technological and formulation innovation:Advanced synthetic cannabinoids and precision medicine approaches improve treatment efficacy and dosing consistency.

European Market Insights

Europe is emerging as a high-potential market with countries such as Germany, the UK, and France driving demand. National medical cannabis programs, reimbursement integration, and increased clinical adoption in neurology departments contribute to growth. Hospital pharmacies serve as primary distribution channels, ensuring controlled administration and specialist access. Sativex also demonstrates meaningful uptake in MS spasticity management.

Challenges

Despite rapid growth, market expansion faces challenges including regulatory complexities, varying reimbursement policies, and residual stigma around cannabis use in some regions. Stakeholders must navigate these barriers to ensure consistent market penetration.

Strategic Implications

For manufacturers: Focus on diversified product portfolios, invest in clinical evidence generation, and expand distribution across hospital and specialty pharmacies.
For healthcare providers: Integrate evidence-based cannabis pharmaceuticals into treatment protocols, particularly for epilepsy, chronic pain, and neurological disorders.
For investors: The market offers high-growth potential, with Europe representing a strategic region for early adoption and regulatory alignment.

Outlook Summary

From 2025 to 2035, the cannabis pharmaceuticals market is poised for unprecedented growth, fueled by regulatory support, clinical validation, technological innovation, and rising patient demand for effective, non-opioid therapies. Europe will play a pivotal role in the global expansion, presenting opportunities for manufacturers, healthcare providers, and investors to advance treatment outcomes and access across therapeutic areas.

Have a specific Requirements and Need Assistant on Report Pricing or Limited Budget please contact us – sales@factmr.com

To View Related Report:

Syndesmosis Repair System Market https://www.factmr.com/report/579/syndesmosis-repair-system-market
Next Generation Wound Closure Device Market https://www.factmr.com/report/582/next-generation-wound-closure-device-market
Paper-Based Diagnostic Test Kit Market https://www.factmr.com/report/583/paper-based-diagnostic-test-kits-market
Pacemaker/Defibrillator Lead Extraction Kits Market
https://www.factmr.com/report/858/pacemaker-defibrillator-lead-extraction-kits-market

About Fact.MR

Fact.MR is a global market research and consulting firm, trusted by Fortune 500 companies and emerging businesses for reliable insights and strategic intelligence. With a presence across the U.S., UK, India, and Dubai, we deliver data-driven research and tailored consulting solutions across 30+ industries and 1,000+ markets. Backed by deep expertise and advanced analytics, Fact.MR helps organizations uncover opportunities, reduce risks, and make informed decisions for sustainable growth.

S. N. Jha
Fact.MR
+ +1 628-251-1583
sales@factmr.com
